# Tolerability and Efficacy of Adjuvant T-DM1 in Patients with HER2 Positive Breast Cancer After Incomplete Pathological Response to Neoadjuvant Chemotherapy Including Anti-HER2 Agents.

> **NCT06272799** · — · RECRUITING · sponsor: **Regina Elena Cancer Institute** · enrollment: 160 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** T-DM1 adjuvant

## Key facts

- **NCT ID:** NCT06272799
- **Lead sponsor:** Regina Elena Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2022-09-20
- **Primary completion:** 2024-09-20
- **Final completion:** 2024-09-20
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06272799

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06272799, "Tolerability and Efficacy of Adjuvant T-DM1 in Patients with HER2 Positive Breast Cancer After Incomplete Pathological Response to Neoadjuvant Chemotherapy Including Anti-HER2 Agents.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06272799. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*